Videshi Pharma Kanpaniyaanne Ke Liye Bhaarat Mein Mushkil Daur

Business »

Videshi Pharma Kanpaniyaanne Ke Liye Bhaarat Mein Mushkil Daur

kiran kaabta somavanshi iteeaaiji malteeneshanal pharma companiyon ke liye yah Bhaarat mein shaayad sabse mushkil daur hai. Pichhle ek varsh mein drag praaising control, lokal jenerik companiyon ko kanpalsari license jaari karne, peteint vaapas lene, ghareloo pharma market ki growth dheemi padne aur ab novaartis ko glaaivek ke peteint ki manjoori na milne jaise kaaranon se in companiyon ki mushkilein badh gayi hain. Dainasen kansalting ke presideint end CEO ajit daangi ka kehna hai, 'Glaaivek ke faisale ke saath hi kanpalsari laaiseinsing ka udaarata se istemaal, pharma mein FDI, price control ka daayara 348 davaaon tak badhaana, traansafar praaising, klinikl trial ko manjoori mein deri jaise mudde research karne waali emaenasi ko Bhaarat mein inavestameint karne se pehle do baar sochane ke liye majaboor kareinge. ' peteint ki teji se eksapaayari, nai davaaon ki khoj mein chunautiyon aur ghatati product paaipalaain ki vajah se jyaadaatar malteeneshanal companiyon ko apne deshon mein pareshaaniyon ka saamana karna pad raha hai. Aise samay mein Bhaarat jaise ubharate hue bade baajaar mein jokhim badhna inke liye ek bura sanket hai. Pichhle 10 varshon mein sheersh 9 pharma emaenasi ki kul sales doguni hui hai aur operating margin 16 se feesadi se badhkar 18.5 feesadi ho gaya hai. Iske mukaabale mein san pharma, Cipla, lyupin aur Dr Reddy'S jaisi jyaadaatar badi bhaarateeya companiyon ki aamdani kai guna badhi hai aur inke margin mein bhi achha sudhaar aaya hai. In ghareloo pharma companiyon ka market kaipitlaaijeshan pichhle dashak mein kaafi teji se badha hai. Doosari or emaenasi mein jeeesake pharma aur ebaut ko chhodkar faainajar, novaartis aur mark jaisi companiyon ka market kaipitlaaijeshan pichhle 10 varshon mein keval doguna huaa hai. In companiyon ke sheyaron par bhi dabaav dikh raha hai. Pichhle ek varsh mein Bhaarat mein emaenasi pharma companiyon ke share BSE helthakeyar index aur jyaadaatar bhaarateeya companiyon ke mukaabale pichhde hain. Faaijar India ke share mein 11 feesadi, novaartis ke share mein 17 feesadi, ebaut ke share mein 10.5 feesadi, vaayeth ke share mein 6 feesadi ki giraavat I hai. Is dauraan BSE helthakeyar index 24 feesadi chadha hai. Emaemasi pharma companiyon ka vailyooeshan bhi inke ghareloo pratidvandviyon ki tulana mein kam hai. Industry ko track karne vaale ek enaalist ka maanana hai , ' chunautiyon ke baavajood Bhaarat ke liye in companiyon ki yojanaaon par jyaada asar naheen padega kyaaneki ye growth ke liye braanded jeneriks par najar rakh rahi hain. ' kaarvi broking ke pharma enaalist Rahul sharma ka kehna hai , ' malteeneshanal pharma companiyaan Bhaarat ko anadekha naheen kar sakti aur inhein chunautiyon ke baavajood Bhaarat mein growth ke raaste khojane honge. ' ye companiyaan market mein pahunch badhaane , alag praaising aur braanded jeneriks manne utarane jaise kadam utha sakti hain.

Videshi Pharma Kanpaniyaanne Ke Liye Bhaarat Mein Mushkil Daur https://www.angrejinews.com/pic/4247